Elsevier

Journal of Controlled Release

Volume 183, 10 June 2014, Pages 18-26
Journal of Controlled Release

Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy

https://doi.org/10.1016/j.jconrel.2014.03.012Get rights and content

Abstract

Direct administration of chemotherapeutic drugs to the lungs significantly enhances drug exposure to lung resident cancers and may improve chemotherapy when compared to intravenous administration. Direct inhalation of uncomplexed or unencapsulated cytotoxic drugs, however, leads to bolus release and unacceptable lung toxicity. Here, we explored the utility of a 56Ā kDa PEGylated polylysine dendrimer, conjugated to doxorubicin, to promote the controlled and prolonged exposure of lung-resident cancers to cytotoxic drug. After intratracheal instillation to rats, approximately 60% of the dendrimer was rapidly removed from the lungs (within 24Ā h) via mucociliary clearance and absorption into the blood. This was followed by a slower clearance phase that reflected both absorption from the lungs (bioavailability 10ā€“13%) and biodegradation of the dendrimer scaffold. After 7Ā days, approximately 15% of the dose remained in the lungs. A syngeneic rat model of lung metastasised breast cancer was subsequently employed to compare the anticancer activity of the dendrimer with a doxorubicin solution formulation after intravenous and pulmonary administration. Twice weekly intratracheal instillation of the dendrimer led to a >Ā 95% reduction in lung tumour burden after 2Ā weeks in comparison to IV administration of doxorubicin solution which reduced lung tumour burden by only 30ā€“50%. Intratracheal instillation of an equivalent dose of doxorubicin solution led to extensive lung-related toxicity and death withinĀ several days of a single dose. The data suggest that PEGylated dendrimers have potential as inhalable drug delivery systems to promote the prolonged exposure of lung-resident cancers to chemotherapeutic drugs and to improve anti-cancer activity.

Introduction

Primary lung cancer is one of the leading causes of death in developed countries and is responsible for 23% of all cancer-related deaths [1]. Primary lung cancers are mainly of epithelial origin and most commonly result from inhaled exposure to cigarette smoke (the main cause of primary lung cancer) and environmental contaminants such as asbestos and radon. The lungs are also a major site of metastasis for other cancers including those of the breast, prostate and colon. These cancers typically metastasise towards the lungs by invading into the blood stream, from where they lodge within the narrow pulmonary capillaries, invade into the surrounding tissue and establish solid secondary tumours. From here, they may metastasise further to thoracic lymph nodes or elsewhere in the body. Despite their prevalence, lung-resident cancers are difficult to treat, and mortality rates with conventional intravenous chemotherapy are high (approximately 85% within 5Ā years) [2]. The lack of efficacy of intravenous chemotherapy against lung tumours stems from a combination of (typically) late diagnosis, and poor drug access to lung tissue after intravenous administration [2], [3], [4], [5]. Inhaled drug delivery results in improved access to lung tissue and has shown superior activity when compared to intravenous administration in both animals and humans [6], [7], [8], [9], [10]. Clinical studies, however, suggest that inhaled delivery of cytotoxic drug alone, leads to high local drug concentrations and unacceptable lung-related toxicity [9], [11], [12].

The realisation that pulmonary delivery of cytotoxic drug may enhance therapy, but is associated with unacceptable toxicity, has stimulated increasing interest in the development of inhaled delivery systems that improve drug exposure to lung-resident tumours, but limit the toxic effects of the drug. Thus, a number of nanoparticulate and liposomal formulations of doxorubicin have been evaluated as potential delivery systems for the improved treatment of lung-resident cancers after inhaled administration [2], [10], [13], [14]. These studies provide promising indications of pre-clinical utility, with reduced lung-related side effects compared to the pulmonary administration of drug alone, and reduced systemic toxicity compared to intravenous drug delivery [2], [10], [13], [14].

The nanoparticulate carriers evaluated to this point, however, have been relatively large (54 to >Ā 600Ā nm) [10], [15], [16], [17], [18], [19], [20]. Absorption across the pulmonary epithelia or diffusion into solid lung tumours is therefore expected to be limited [21], [22], [23], [24]. For colloidal carriers, such as liposomes (reviewed in [25]), drug release is also usually non-specific, providing limited control over the kinetics of drug release [2], [26]. Finally, for non-biodegradable particles that are retained in the lungs for extended periods of time, there are increasing risks of toxicity via the promotion of localised infiltration of alveolar macrophages and inflammation in response to the presence of the particles [27], [28].

In contrast, dendritic polymers (dendrimers) [29], [30] are approximately one order of magnitude smaller (approx 4ā€“20Ā nm) than the majority of nanoparticles and liposomes, and therefore provide possible advantage with respect to the efficiency of interstitial diffusion, the extent of absorption and the degree of tumour penetration [31]. Drug conjugation to the dendrimer scaffold via linkers that are cleaved selectively in the environment of a tumour also provides a greater level of control over the location and kinetics of drug release [32]. Dendrimers based on poly-amino acid structures are also biodegradable, reducing the potential for immune stimulation. The kinetics of dendrimer clearance from the lungs of rats were therefore recently evaluated using PEGylated systems based on a poly-L-lysine scaffold. Small PEGylated dendrimers (<Ā 20Ā kDa) were absorbed after pulmonary instillation as low molecular weight fragments following initial degradation in the lungs. In contrast, increasing the molecular weight of the PEGylated dendrimers led to increased metabolic stability and significant lung retention [33]. PEGylated dendrimer based delivery systems therefore have the potential to provide controlled and site specific drug delivery to lung resident tumours. For these systems, programmed drug liberation followed by metabolic breakdown is expected to provide advantage over other colloidal or particulate vehicles as inhalable drug delivery systems for chemotherapeutic drugs.

In the current study, we have explored whether a 56Ā kDa biodegradable PEGylated polylysine dendrimer, conjugated with doxorubicin via an acid labile linker (Fig.Ā 1, described previously [34]) provides therapeutic benefit against lung-resident cancers when compared to the inhaled or intravenous administration of solution formulations of drug alone. Since a lack of understanding of the mechanisms by which nanomedicines are cleared from the lungs is also a significant current limitation to the translation of inhalable nanomedicine technologies into human clinical trials, the mechanisms and time course of dendrimer (and associated doxorubicin) clearance from the lungs have also been evaluated in detail.

Section snippets

Materials and reagents

Doxorubicin, thiazolyl blue formazan (MTT) and heptanesulphonic acid were purchased from Sigma-Aldrich (Sydney, Australia). RPMI media, hanks balanced salt solution (HBSS), penicillin/streptomycin, fetal bovine serum and glutamax were obtained from Gibco (NY, USA). Soluene-350 and IRGASafe scintillant were from Packard Biosciences (Meriden, CT). Cell culture flasks and microplates were from Corning (NY, USA). Polyethylene tubing (0.96Ā Ć—Ā 0.58Ā mm external and internal diameter) was purchased from

Pharmacokinetics and biodistribution of D-DOX and doxorubicin after pulmonary instillation to rats

Pulmonary instillation of doxorubicin alone led to rapid and essentially complete absorption (Fabs 96%, Fig.Ā 2A, TableĀ 1). Following the peak in plasma concentrations 5Ā min after dosing, plasma concentrations of doxorubicin remained higher than in rats administered IV doxorubicin due to the continual absorption of drug from the lungs (Fig.Ā 2A). However, after 24Ā h, only 5% of the initial pulmonary dose of doxorubicin was quantifiable in the lungs (Fig.Ā 2D, E), and this was mainly associated with

Discussion

Pulmonary administration of cytotoxic drugs can improve chemotherapy against lung-resident cancers, but is usually associated with significant toxicity due to the exposure of non-cancerous lung tissue to high localised concentrations of the cytotoxic agent [9]. Interest has therefore increased in the development of inhalable drug delivery systems that enable the prolonged and controlled exposure of lung-resident cancers to chemotherapeutic drugs, and that simultaneously limit lung-associated

Acknowledgments

The authors would like to thank Erica Sloan for her assistance in transfecting the cells. This work was supported by an Australian Research Council Linkage grant. LMK was supported by an NHMRC CDF.

References (54)

  • L.M. Kaminskas et al.

    Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker

    J. Control. Release

    (2011)
  • L.M. Kaminskas et al.

    A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems

    Nanomedicine

    (2012)
  • G.M. Ryan et al.

    PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin

    J. Control. Release

    (2013)
  • L.M. Kaminskas et al.

    PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

    J. Control. Release

    (2013)
  • L.M. Kaminskas et al.

    PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats

    J. Control. Release

    (2009)
  • L.M. Kaminskas et al.

    Partly-PEGylated poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers

    J. Pharm. Sci.

    (2009)
  • L.A. Dailey et al.

    Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung

    Toxicol. Appl. Pharmacol.

    (2006)
  • L.E. Quint et al.

    Distribution of distant metastases from newly diagnosed non-small cell lung cancer

    Ann. Thorac. Surg.

    (1996)
  • K.M. Al-Hallak et al.

    Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?

    Eur. J. Pharm. Biopharm.

    (2010)
  • A. Jemal et al.

    Global Cancer Stat

    (2011)
  • P. Zarogoulidis et al.

    Inhaled chemotherapy in lung cancer: future concept of nanomedicine

    Int. J. Nanomedicine

    (2012)
  • J.H. Kang et al.

    Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells

    BMC Cancer

    (2011)
  • T.E. Murdter et al.

    Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP)

    Pneumologie

    (2000)
  • C.F. Verschraegen et al.

    Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies

    Clin. Cancer Res.

    (2004)
  • G.A. Otterson et al.

    Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs

    Clin. Cancer Res.

    (2007)
  • B.P. Wittgen et al.

    Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung

    Clin. Cancer Res.

    (2007)
  • F. Gagnadoux et al.

    Aerosolized chemotherapy

    J. Aerosol Med. Pulm. Drug Deliv.

    (2008)
  • Cited by (0)

    View full text